ERBB2 and cancer: Bispecific antibodies targeting both Her2 and Her3,18 targeting two different epitopes of Her2,19, 20 or engaging T cells to Her2 cancer cells by targeting Her2 and CD321 have also exhibited encouraging results in phase I or pre-clinical studies.